Sol Gel Technologies Ltd 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Sol Gel Technologies Ltd in the fourth quarter 2025?
Sol gel Technologies Ltd achieved a return on average equity (ROE) of 22.45 % in its fourth quarter 2025, this is above SLGL's average return on equity of -39.81%.
Sol Gel Technologies Ltd shareholder's equity over the 12 months ending in its fourth quarter 2025 are valued at $24 million

While the company's net income was fading, Sol Gel Technologies Ltd was able to improve its ROE compared to the third quarter 2025.

Within the Major Pharmaceutical Preparations industry 135 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 3123 to 3144.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Equity Change	-20.93 %	-20.93 %	-8.65 %	-38.22 %	-
Y / Y Net Income Change	-	-	487.55 %	-	-
Net Income (TTM) in Millions	5	1	1	-9	-9
Return On Equity (TTM)	22.45 %	3.97 %	3.75 %	-30.52 %	-27.48 %
SLGL's Total Ranking	# 3144	# 3123	#	#	#
Equity (TTM) in Millions	23	23	32	20	29
Seq. Equity Change	0 %	-28.45 %	58.05 %	-30.08 %	0 %
Seq. Net Income Change	-	-	-	-	-

Back to SLGL Management Effectiveness >> SLGL's 5 Years Annual ROE >> Compare SLGL ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 136
Sector	# 360
Overall	# 3144

Return On Equity Statistics
High	Average	Low
5.79 %	-39.81 %	-70.48 %
		(Dec 31 2023)

SLGL Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	23	29	39	42	56
Y / Y Equity Change	-20.93 %	-25.34 %	-8.45 %	-24.07 %	9.33 %
Net Income in Millions	-6	-11	-27	-15	3
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-26.86 %	-36.67 %	-70.48 %	-35.35 %	5.79 %

Back to SLGL Management Effectiveness >> SLGL's 5 Years Annual ROE >> Compare SLGL ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
SLGL's' Return on Equity at Yahoo Finance
SLGL's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SLGL's Competitors
Subscribers only: Roe for Sol Gel Technologies Ltd 's Suppliers
Subscribers only: Return On Equity for SLGL's Customers

Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector	ROE
Dariohealth Corp	59.48 %
Nrc Health	58.51 %
Zoetis Inc	56.31 %
Alpha Tau Medical Ltd	55.29 %
Transmedics Group Inc	53.88 %
Pulmatrix Inc	53.50 %
Abeona Therapeutics Inc	53.18 %
Novo Nordisk A	52.79 %
Medinotec Inc	52.76 %
Concentra Group Holdings Parent Inc	47.62 %
Theravance Biopharma inc	46.03 %
Galmed Pharmaceuticals Ltd	43.72 %
Acadia Pharmaceuticals Inc	41.90 %
Arrowhead Pharmaceuticals Inc	41.16 %
Gilead Sciences Inc	41.14 %
Tenet Healthcare Corp	40.89 %
Agilent Technologies inc	40.80 %
Gsk Plc	39.41 %
Bristol myers Squibb Company	39.17 %
Hutchmed china Limited	36.98 %
Oramed Pharmaceuticals Inc	36.81 %
Solventum Corporation	36.74 %
Newgenivf Group Limited	36.53 %
Merck and Co Inc	36.16 %
Adma Biologics Inc	34.98 %
Illumina Inc	34.94 %
Compugen Ltd	34.40 %
Vaxart Inc	33.83 %
Johnson and Johnson	33.78 %
Dexcom Inc	32.44 %

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.